AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1745715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.94 mg)
Number of subjects: 9
Study 1745715 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 9
Study 6815252 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms of aerosolized terbutaline
Number of subjects: 13
Study 6815252 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of aerosolized terbutaline q.i.d.
Number of subjects: 13
Study 30060087 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared coagulation (IRC) ablation
Number of subjects: 120
Study 30060087 — intervention group
Group type: COMPARATOR
Intervention: Active monitoring (AM)
Number of subjects: 120
Study 28273202 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary psychoeducation-based intervention
Number of subjects: 183
Study 28273202 — intervention group
Group type: COMPARATOR
Intervention: Traditional intervention
Number of subjects: 183
Study 26090758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Number of subjects: 46
Study 24669858 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional compression shorts (CoreShort PRO, Under Armour, USA)
Number of subjects: 29
Study 24669858 — intervention group
Group type: COMPARATOR
Intervention: Non-directional compression shorts (HeatGear, Under Armour, USA)
Number of subjects: 29
Study 22221461 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher-designed word-problem intervention
Number of subjects: 31
Study 22221461 — intervention group
Group type: COMPARATOR
Intervention: Researcher-designed calculation intervention
Number of subjects: 31
Study 22221461 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual (teacher-designed) control
Number of subjects: 31
Study 18614145 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education e‐mails on prostate cancer (PC) and prostate‐specific antigen (PSA) screening
Number of subjects: 115
Study 18614145 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education e‐mails on benign prostatic hyperplasia (BPH) and erectile dysfunction (ED)
Number of subjects: 115
Study 17490769 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for benign disorders (specific details not provided)
Number of subjects: 0
Study 15612833 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene treatment
Number of subjects: 0
Study 11386605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting venous plasma glucose (FPG) measurement in low-risk population (n=424)
Number of subjects: 726
Study 11386605 — intervention group
Group type: COMPARATOR
Intervention: Comparison with WHO and ADA recommendations
Number of subjects: 726
Study 11386605 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclassification of reference population
Number of subjects: 726
Study 9678282 — intervention group
Group type: COMPARATOR
Intervention: Probucol (500 mg/day)
Number of subjects: 126
Study 9678282 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol (200 mg/day)
Number of subjects: 126
Study 9678282 — intervention group
Group type: COMPARATOR
Intervention: Probucol plus cilostazol
Number of subjects: 126
Study 9678282 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 8067708 — intervention group
Group type: EXPERIMENTAL
Intervention: CFA (Colony Forming Assay)
Number of subjects: 70
Study 8067708 — intervention group
Group type: EXPERIMENTAL
Intervention: MTT-test
Number of subjects: 70
Study 8067708 — intervention group
Group type: COMPARATOR
Intervention: ACNU or BCNU (adjuvant chemotherapy)
Number of subjects: 70
Study 3058088 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate withdrawal
Number of subjects: 0
Study 3058088 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate withdrawal for two summers
Number of subjects: 0
Study 3058088 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate treatment
Number of subjects: 0
Study 30423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Current alcohol use disorder
Number of subjects: 675
Study 30423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial personality disorder
Number of subjects: 675
Study 30423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rates of current manic episode
Number of subjects: 675
Study 30423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher current illness severity (CGI score)
Number of subjects: 675
Study 30423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder diagnosis
Number of subjects: 675
Study 30423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 675
Study 30423419 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant consumption
Number of subjects: 675
Study 28270194 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (ABI), a 20 min motivational counselling interview
Number of subjects: 10
Study 28270194 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Brief Intervention (ABI)
Number of subjects: 10
Study 28270194 — intervention group
Group type: COMPARATOR
Intervention: Hospital admission
Number of subjects: 10
Study 28270194 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a 'significant other'
Number of subjects: 10
Study 28270194 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpose or structure with activities linked to employment/social/leisure pursuits
Number of subjects: 10
Study 26322544 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Lactobacillus rhamnosus GG
Number of subjects: 59
Study 26322544 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated Lactobacillus rhamnosus GG
Number of subjects: 59
Study 26322544 — intervention group
Group type: COMPARATOR
Intervention: Control juice
Number of subjects: 59
Study 23611212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg orally daily
Number of subjects: 37
Study 23611212 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg orally daily
Number of subjects: 37
Study 20800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) with 800 cGy delivered in two 200‐cGy fractions twice a day before CD34(+) selected autologous hematopoietic stem cell transplantation.
Number of subjects: 11
Study 20800376 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney shielding techniques using ultrasound (US) and noncontrast computerized tomography (CT) or CT imaging alone.
Number of subjects: 11
Study 18753213 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography and IEGM methods for VV delay optimization during exercise
Number of subjects: 24
Study 18753213 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography and IEGM methods for AV delay optimization during exercise
Number of subjects: 24
Study 17146008 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐ECT (10 treatments)
Number of subjects: 201
Study 17146008 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐Pharm (lithium carbonate plus nortriptyline hydrochloride for 6 months)
Number of subjects: 201
Study 17146008 — intervention group
Group type: COMPARATOR
Intervention: C‐ECT
Number of subjects: 201
Study 17146008 — intervention group
Group type: COMPARATOR
Intervention: C‐Pharm
Number of subjects: 201
Study 14762617 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for epilepsy treatment based on the opinion of Brazilian experts
Number of subjects: 0
Study 14762617 — intervention group
Group type: COMPARATOR
Intervention: North-American guidelines
Number of subjects: 0
Study 10750067 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron/folate supplementation
Number of subjects: 0
Study 10750067 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron/folate supplementation with added vitamin C
Number of subjects: 0
Study 10750067 — intervention group
Group type: COMPARATOR
Intervention: Once-weekly iron/folate supplementation
Number of subjects: 0
Study 8956375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 30
Study 8956375 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 30
Study 8956375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1549934 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual increase of isoflurane concentration from 0.5% to 3%
Number of subjects: 20
Study 1549934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudden increase of isoflurane concentration from 0.5% to 3%
Number of subjects: 20
Study 3545900 — intervention group
Group type: EXPERIMENTAL
Intervention: Rengasil
Number of subjects: 0
Study 3545900 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 0
Study 3545900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31274545 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 20ml of ropivacaine 0.375% + 75μg of clonidine
Number of subjects: 182
Study 31274545 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM) with 100μg of morphine
Number of subjects: 182
Study 31274545 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block
Number of subjects: 182
Study 31274545 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine (ITM)
Number of subjects: 182
Study 31274545 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 182
Study 29386253 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in the caudal zona incerta (cZi)
Number of subjects: 25
Study 29386253 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 25
Study 26899568 — intervention group
Group type: EXPERIMENTAL
Intervention: High roasted coffee (HRC)
Number of subjects: 12
Study 26899568 — intervention group
Group type: EXPERIMENTAL
Intervention: Low roasted coffee (LRC)
Number of subjects: 12
Study 26899568 — intervention group
Group type: EXPERIMENTAL
Intervention: Unroasted coffee (URC)
Number of subjects: 12
Study 26899568 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro hydrolyzed unroasted coffee (HURC)
Number of subjects: 12
Study 24656784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-led intervention to increase hand hygiene behavior
Number of subjects: 17
Study 24656784 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation
Number of subjects: 17
Study 24656784 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitators of implementation
Number of subjects: 17
Study 24656784 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for improvement
Number of subjects: 17
Study 23153344 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (60% of 1-Repetition Maximum, for 12 weeks)
Number of subjects: 45
Study 20605441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 10 mg
Number of subjects: 48
Study 20605441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine 20 mg
Number of subjects: 48
Study 20605441 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine 10 mg
Number of subjects: 48
Study 20605441 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 48
Study 17921382 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU as retinyl palmitate)
Number of subjects: 404
Study 17921382 — intervention group
Group type: COMPARATOR
Intervention: Iodine supplementation (191 mg I as oral iodized oil)
Number of subjects: 404
Study 17921382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of iodine and vitamin A supplementation
Number of subjects: 404
Study 17921382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 15505638 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/Met variant (rs4680)
Number of subjects: 107
Study 15505638 — intervention group
Group type: EXPERIMENTAL
Intervention: rs4633 variant
Number of subjects: 107
Study 15505638 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-marker haplotype (rs737865-rs4680-rs165599)
Number of subjects: 107
Study 12562409 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA™
Number of subjects: 120
Study 12562409 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway with open drainage tube
Number of subjects: 120
Study 12562409 — intervention group
Group type: COMPARATOR
Intervention: Standard laryngeal mask airway
Number of subjects: 120
Study 12562409 — intervention group
Group type: COMPARATOR
Intervention: SLIPA™ and standard laryngeal mask airway
Number of subjects: 120
Study 10384900 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital hearing aid (Senso)
Number of subjects: 28
Study 10384900 — intervention group
Group type: COMPARATOR
Intervention: Analogue hearing aid (Logo)
Number of subjects: 28
Study 8696714 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP regimen (mitomycin C 6 mg/m2 on day 1, ifosfamide 1500 mg/m2 on days 1-3, cisplatin 30 mg/m2 on days 1-3 every 4 weeks)
Number of subjects: 72
Study 8696714 — intervention group
Group type: EXPERIMENTAL
Intervention: MIP regimen
Number of subjects: 72
Study 1948213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (500 mg bid or qid)
Number of subjects: 72
Study 1948213 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (300 or 400 mg bid)
Number of subjects: 72
Study 6657039 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30264137 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy (dCBT)
Number of subjects: 1711
Study 29528863 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 296
Study 29528863 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 296
Study 26545405 — intervention group
Group type: COMPARATOR
Intervention: BMI < 25
Number of subjects: 15538
Study 26545405 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide treatment
Number of subjects: 15538
Study 26545405 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-positive disease
Number of subjects: 15538
Study 24694986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 108
Study 24694986 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-producing fruits and vegetables
Number of subjects: 108
Study 24694986 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 108
Study 22162050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital tirofiban
Number of subjects: 1398
Study 20669815 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% strontium acetate and 1040 ppm fluoride dentifrice (test dentifrice)
Number of subjects: 79
Study 20669815 — intervention group
Group type: COMPARATOR
Intervention: 1450 ppm fluoride dentifrice (control dentifrice)
Number of subjects: 79
Study 17643586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 120
Study 17643586 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide
Number of subjects: 120
Study 17643586 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban + clopidogrel 600-mg loading dose
Number of subjects: 120
Study 17643586 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide + clopidogrel 600-mg loading dose
Number of subjects: 120
Study 16046365 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention (up to six 30-minute sessions focused on cardiac-related fears)
Number of subjects: 100
Study 16046365 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study 12029281 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnorelaxation
Number of subjects: 40
Study 12029281 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal appliance
Number of subjects: 40
Study 12029281 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment
Number of subjects: 40
Study 9809692 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol restriction (maximum of 15 mL/day)
Number of subjects: 34
Study 9809692 — intervention group
Group type: COMPARATOR
Intervention: Constant drinking habits
Number of subjects: 34
Study 7631286 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocking agents
Number of subjects: 0
Study 7631286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 7631286 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 7631286 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist + beta-blocking agent
Number of subjects: 0
Study 2575833 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg pindolol
Number of subjects: 0
Study 2575833 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg pindolol
Number of subjects: 0
Study 2575833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 675837 — intervention group
Group type: EXPERIMENTAL
Intervention: trichlorophone
Number of subjects: 18
Study 675837 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 18
Study 675837 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole
Number of subjects: 18
Study 675837 — intervention group
Group type: COMPARATOR
Intervention: metronidazole, tinidazole, mebendazole, trichlorophone, oxamniquine and pyrantel pamoate
Number of subjects: 18
Study 30832198 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalysis (PA)
Number of subjects: 169
Study 30832198 — intervention group
Group type: COMPARATOR
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 169
Study 28973024 — intervention group
Group type: EXPERIMENTAL
Intervention: Armeo-Power training with muscle vibration (group-A)
Number of subjects: 20
Study 28973024 — intervention group
Group type: COMPARATOR
Intervention: Armeo-Power training without muscle vibration (group-B)
Number of subjects: 20
Study 25633573 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol 1 mcg administered orally once daily for three months
Number of subjects: 60
Study 25633573 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally once daily for three months
Number of subjects: 60
Study 23046418 — intervention group
Group type: EXPERIMENTAL
Intervention: LOOSE (n = 15) - instructed to 'keep the ball away from the loose defender'
Number of subjects: 46
Study 23046418 — intervention group
Group type: EXPERIMENTAL
Intervention: TTF (n = 15) - instructed to 'take the first option'
Number of subjects: 46
Study 23046418 — intervention group
Group type: COMPARATOR
Intervention: NI (control) (n = 16) - given no instructions
Number of subjects: 46
Study 22130240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous bolus
Number of subjects: 48
Study 22130240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg intravenous bolus
Number of subjects: 48
Study 22130240 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.05 mg/kg intravenous bolus
Number of subjects: 48
Study 22130240 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per hour infusion for 4 h
Number of subjects: 48
Study 22130240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 19585825 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting nifedipine (Nicardia retard 10/20/30 CD)
Number of subjects: 1632
Study 16719648 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based predictions of psychological experiments in the distant future
Number of subjects: 0
Study 16719648 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictions of performance on near and distant future tests
Number of subjects: 0
Study 15253685 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1b (Betaseron)
Number of subjects: 0
Study 15253685 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) IFNbeta-1a (Avonex)
Number of subjects: 0
Study 15253685 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (s.c.) IFNbeta-1a (Rebif)
Number of subjects: 0
Study 15253685 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta products
Number of subjects: 0
Study 11693798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (30 mg/m2 daily for 3 days) + Vindesine (2.5 mg/m2 only day 1) + Dacarbazine (DTIC) (250 mg/m2 daily for 3 consecutive days) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Number of subjects: 51
Study 11693798 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) (800 mg/m2 day 1) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Number of subjects: 51
Study 9350957 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HAD)
Number of subjects: 0
Study 8204227 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg/kg of i.v. ketorolac
Number of subjects: 50
Study 8204227 — intervention group
Group type: COMPARATOR
Intervention: No additional analgesic (morphine only group)
Number of subjects: 50
Study 3311438 — intervention group
Group type: EXPERIMENTAL
Intervention: One tablet of Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine)
Number of subjects: 150
Study 3311438 — intervention group
Group type: EXPERIMENTAL
Intervention: Two tablets of Fansimef
Number of subjects: 150
Study 3311438 — intervention group
Group type: EXPERIMENTAL
Intervention: Three tablets of Fansimef
Number of subjects: 150
Study 3311438 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 31561648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA)
Number of subjects: 205
Study 31561648 — intervention group
Group type: COMPARATOR
Intervention: Geniculate local anesthetic block
Number of subjects: 205
Study 31561648 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated procedure (n = 43)
Number of subjects: 205
Study 31561648 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA; n = 21)
Number of subjects: 205
Study 28140486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 30
Study 28140486 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 30
Study 28140486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 30
Study 25762805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital hypothermia
Number of subjects: 508
Study 25762805 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 508